| Purpose | BGI’s SENTIS™ Cancer+ Discovery Panel, the most comprehensive and accurate NGS-based testing solution for the identification of actionable somatic and germline mutations and the discovery of novel variants with important functions in cancer. The panel offers exon coverage of 688 cancer-related genes and interrogates the most common types of alterations, including SNVs, indels, CNVs and fusions in solid tumors. |
| Test Code | DX0644 |
| Turnaround Time (TAT) | 20 Days |
| Sample Tested | BGI SENTISTM Cancer+Discovery (ctDNA)- ≥10mL of peripheral blood (separated plasma and formed elements) OR
- ≥8mL of peripheral blood collected in Streck Cell-Free DNA BCT® tube
|
| Methodology | - DNA Extraction and QC
- Targeted Capture of 688 cancer-related genes
- NGS Sequencing and Data Analysis for pathogenic mutations
- Reports having information for targeted drugs (Precision Medicine)
- Genetic Counselling
|
| Advantages | - Identification of mutations in genes relevant to both sporadic and hereditary cancers
- Information on targeted drugs (>300 drugs)
- Ability to analyse 425 genes in cancer-related pathways for discovery of novel pathogenic variants
- Panel standard sequencing coverage ≥900X
|
